Hims & Hers Health Inc is trading 7.4% up today at $30.24, extending a multi-day rally. The surge is significantly driven by Barclays maintaining an "Overweight" rating and raising its price target from $29 to $39 on June 18, 2026. Analysts also cite continued optimism around the company's GLP-1 weight-loss business, upcoming FDA decision on peptides, and the recent acquisition of Eucalyptus as contributing factors.